Suppr超能文献

锕-225 用于靶向 α 治疗:配位化学和当前螯合方法。

Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

机构信息

Department of Chemistry and Chemical Biology, Cornell University , Ithaca, New York.

出版信息

Cancer Biother Radiopharm. 2018 Oct;33(8):336-348. doi: 10.1089/cbr.2018.2494. Epub 2018 Jun 11.

Abstract

The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT. This overview provides a starting point for researchers in the field of TAT to gain an understanding of this valuable therapeutic radionuclide.

摘要

发射 α 粒子的放射性核素锕-225 具有在靶向 α 治疗 (TAT) 中应用的有前景的核特性,这是一种利用 α 粒子发射来破坏肿瘤的治疗策略。然而,可能阻碍锕-225 临床应用的一个关键因素是对其配位化学的了解不足,这为开发适合该离子的螯合策略带来了挑战。在本文中,我们提供了对已知锕化学的概述,并总结了已探索用于基于锕-225 的 TAT 的螯合剂。该概述为 TAT 领域的研究人员提供了一个起点,以了解这种有价值的治疗性放射性核素。

相似文献

1
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Cancer Biother Radiopharm. 2018 Oct;33(8):336-348. doi: 10.1089/cbr.2018.2494. Epub 2018 Jun 11.
2
Actinium-225 targeted alpha particle therapy for prostate cancer.
Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024.
3
Targeted alpha therapy: part I.
Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176.
4
Actinium chelation and crystallization in a macromolecular scaffold.
Nat Commun. 2024 Jul 15;15(1):5741. doi: 10.1038/s41467-024-50017-5.
7
Alpha emitting nuclides for targeted therapy.
Nucl Med Biol. 2021 Jan;92:228-240. doi: 10.1016/j.nucmedbio.2020.08.004. Epub 2020 Sep 1.
8
A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Chem Biol Drug Des. 2023 Nov;102(5):1276-1292. doi: 10.1111/cbdd.14311. Epub 2023 Sep 15.
9
Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225.
Q J Nucl Med Mol Imaging. 2020 Sep;64(3):265-277. doi: 10.23736/S1824-4785.20.03266-5. Epub 2020 May 21.
10
Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Nucl Med Biol. 2015 May;42(5):428-438. doi: 10.1016/j.nucmedbio.2014.12.007. Epub 2014 Dec 20.

引用本文的文献

2
Light-Induced Synthesis and Radiotheranostic Treatment of Gastric Cancer with Tb-Labeled Monoclonal Antibodies.
JACS Au. 2025 May 22;5(6):2606-2618. doi: 10.1021/jacsau.5c00219. eCollection 2025 Jun 23.
3
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with Ac.
EJNMMI Radiopharm Chem. 2025 Apr 4;10(1):16. doi: 10.1186/s41181-025-00337-8.
4
New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.
Anticancer Agents Med Chem. 2025;25(16):1198-1217. doi: 10.2174/0118715206357095250306051714.
5
Towards DFO*-Preliminary Results of a New Chelator for the Complexation of Actinium-225.
Pharmaceutics. 2025 Mar 1;17(3):320. doi: 10.3390/pharmaceutics17030320.
6
The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.
Molecules. 2025 Mar 13;30(6):1296. doi: 10.3390/molecules30061296.
7
Ac-225 radiochemistry through the lens of [Ac]Ac-DOTA-TATE.
EJNMMI Radiopharm Chem. 2025 Feb 20;10(1):9. doi: 10.1186/s41181-025-00332-z.
8
Radiotheranostic landscape: A review of clinical and preclinical development.
Eur J Nucl Med Mol Imaging. 2025 Feb 1. doi: 10.1007/s00259-025-07103-7.
10
Study on the sorption and desorption behavior of La and Bi by bis(2-ethylhexyl)phosphate modified activated carbon.
RSC Adv. 2024 Nov 1;14(47):34855-34867. doi: 10.1039/d4ra06276k. eCollection 2024 Oct 29.

本文引用的文献

1
In vitro evaluation of Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme.
Chem Biol Drug Des. 2018 Jul;92(1):1344-1356. doi: 10.1111/cbdd.13199. Epub 2018 Apr 23.
2
Functionalized TiO nanoparticles labelled with Ac for targeted alpha radionuclide therapy.
J Nanopart Res. 2018;20(3):83. doi: 10.1007/s11051-018-4181-y. Epub 2018 Mar 20.
3
Evaluation of an Anti-HER2 Nanobody Labeled with Ac for Targeted α-Particle Therapy of Cancer.
Mol Pharm. 2018 Apr 2;15(4):1457-1466. doi: 10.1021/acs.molpharmaceut.7b00985. Epub 2018 Mar 7.
4
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.
Target Oncol. 2018 Apr;13(2):189-203. doi: 10.1007/s11523-018-0550-9.
6
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717. doi: 10.1002/anie.201709532. Epub 2017 Oct 16.
7
Octadentate Picolinic Acid-Based Bispidine Ligand for Radiometal Ions.
Chemistry. 2017 Nov 13;23(63):15945-15956. doi: 10.1002/chem.201702284. Epub 2017 Oct 17.
8
Improved Ac daughter retention in InPO containing polymersomes.
Appl Radiat Isot. 2017 Oct;128:183-189. doi: 10.1016/j.apradiso.2017.07.030. Epub 2017 Jul 16.
9
10
Synthesis and Characterization of the Actinium Aquo Ion.
ACS Cent Sci. 2017 Mar 22;3(3):176-185. doi: 10.1021/acscentsci.6b00356. Epub 2017 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验